molecule-computer.jpgIPNews® – Humanetics announced that after years of research and development with Mount Sinai Medical School, it has been granted a patent for its Alzheimer’s disease treatment. 

The newly patented compound NIC5-15 includes methodology for preventing the formation of beta-amyloid plaques, which is widely believed to be the leading cause of Alzheimer’s disease.  The Minnesota based company also reported that its product is concurrently undergoing clinical trials in the New York area.  To continue reading, click: Humanetics Alzheimer’s Patent